Načítá se...
Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases
PURPOSE: Ranibizumab is used in the treatment of choroidal neovascularization (CNV). Although systemic exposure to ranibizumab is low after ocular administration, its mechanism of action must be regarded as potentially teratogenic and embryo-fetotoxic. Women are advised to wait 3 months after the la...
Uloženo v:
| Vydáno v: | Eye (Lond) |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5898875/ https://ncbi.nlm.nih.gov/pubmed/29350689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/eye.2017.305 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|